BIO Industry Analysis Reports
Download past BIO Industry Analysis reports, and sign up to be notified of upcoming reports.
This report by BIO’s Industry Analysis team examines recent investment trends in pain and addiction innovation and the current clinical pipeline for new therapeutics.
Download slides from #BIO2022 on the state of emerging therapeutic companies.
This report investigates recent investment into antibacterial innovation and the current clinical pipeline that will help bridge the gaps in the antibacterial armamentarium.
Emerging Therapeutic Company Investment and Deal Trends
New BIO Industry Analysis trend data have been released for Emerging Therapeutic Company Investment, R&D-Stage Out-licensing, and Acquisitions.
COVID-19 Therapeutic Development Tracker
BIO’s Industry Analysis Team has reviewed and annotated pipeline data from BioCentury and Biomedtracker to create an interactive view of the COVID-19 pipeline. New data released every Monday!
FDA Approvals & Clinical Development Pipeline
BIO’s Industry Analysis Team presents FDA Approval Trends that are filterable by various attributes including: size of company, molecule size, disease area, and various expedited approval pathways.
BIO, QLS Advisors, and Informa Pharma Intelligence have released a new report on clinical development success rates covering 2011-2020.